Quest Diagnostics has added Guardant Health’s Shield colorectal cancer screening test to its nationwide laboratory network, making the first FDA‑approved blood‑based screening option for average‑risk adults 45 and older available to clinicians across the United States. The Shield test can be ordered and collected through Quest’s extensive phlebotomy and laboratory infrastructure, which includes roughly 2,000 patient service centers and 6,000 in‑office phlebotomists. By integrating Shield into its advanced diagnostics suite, Quest is positioning itself to capture a growing market for precision‑medicine services and to improve screening adherence, with Shield’s 93% adherence rate demonstrating a strong potential to increase the number of patients who complete colorectal cancer screening.
The partnership aligns with Quest’s broader strategy to shift toward higher‑margin, high‑volume testing. In the most recent fiscal year, Quest reported $11.04 billion in revenue, up 11.8% from 2024, and adjusted diluted earnings per share of $9.85. Guidance for 2026 revenue is $11.70 billion to $11.82 billion, reflecting confidence that new high‑margin offerings like Shield will contribute to continued top‑line growth. The Shield test’s addition is expected to strengthen Quest’s advanced diagnostics segment, which has been a key driver of the company’s recent revenue expansion.
From a competitive standpoint, the Shield partnership gives Quest a distinct advantage over rivals such as Labcorp, which has not yet secured a comparable FDA‑approved blood‑based colorectal cancer screening test. By offering a convenient, non‑invasive screening option, Quest can attract clinicians who are looking to improve patient compliance and reduce the burden of traditional colonoscopy or stool‑based tests.
While the announcement does not include a direct statement from Quest’s leadership, the move is consistent with CEO Jim Davis’s emphasis on expanding precision‑medicine services. The Shield test’s high‑margin profile is expected to help offset any pressure on Quest’s operating margin, which was 15.3% in Q1 2025 and 14.5% in Q4 2025, and to support the company’s goal of maintaining profitability as it scales its advanced diagnostics portfolio.
Overall, the Shield partnership represents a strategic milestone for Quest Diagnostics, expanding its product offerings, enhancing its competitive positioning, and reinforcing its focus on high‑margin precision‑medicine services. The addition is likely to have a positive impact on Quest’s revenue mix and long‑term growth trajectory.
revised_sentiment_rating
}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.